Benefits and costs of screening Ashkenazi Jewish women for BRCA1 and BRCA2

Journal of Clinical Oncology

Volumn 17, Issue 2, 1999, Pages 494-500

  Grann, Victor R ^a   Whang, William ^a   Jacobson, Judith S ^a   Heitjan, Daniel F ^a   Antman, Karen H ^a   Neugut, Alfred I ^a  

^a New York Presbyterian Columbia University Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BREAST CANCER; CANCER RISK; CANCER SCREENING; CANCER SURVIVAL; COST BENEFIT ANALYSIS; GENE MUTATION; GENETIC SCREENING; HUMAN; JEW; MODEL; OVARIECTOMY; OVARY CANCER; PRIORITY JOURNAL; SYSTEM ANALYSIS;

EID: 0033015788     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.2.494     Document Type: Article

References (33)

1. Bodenheimer TS, Grumbach K: Understanding Health Policy: A Clinical Approach. Norwalk, CT, Appleton and Lange, 1995, pp 143-145
2. Schwitzer SO: Cost effectiveness of early detection of disease. Health Serv Res 9:22-32, 1974
3. Eddy DM: Screening for cervical cancer. Ann Intern Med 113:214-226, 1990
4. Eddy DM: Screening for breast cancer. Ann Intern Med 111:389-399, 1989
5. Salzmann P, Kerlikowske K, Phillips K: Cost-effectiveness of extending screening mammography guidelines to include women 40 to 49 years of age. Ann Intern Med 127:955-965, 1997
6. Neuhauser D, Lewicki AM: National health insurance and the sixth stool guaiac. Policy Anal 2:175-196, 1975
7. Miki Y, Swensen J, Shattuck-Eidens D, et al: Isolation of BRCA1, the 17q-linked breast and ovarian cancer susceptibility gene. Science 266:66-71, 1994
8. Wooster R, Neuhausen SL, Mangion J, et al: Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Nature 378:789-791, 1995
9. Struewing JP, Hartge P, Wacholder S, et al: The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 336:1401-1408, 1997
10. Schrag D, Kuntz KM, Garber JE, et al: Decision analysis: Effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. N Engl J Med 336:1464-1471, 1997
11. Grann VR, Whang W, Panageas K, et al: A decision analysis of prophylactic mastectomy and oophorectomy in BRCA1 or BRCA2 positive patients. J Clin Oncol 16:979-985, 1998
12. Tonin P, Weber B, Offitt K, et al: Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families. Nat Med 2:1179-1183, 1996
13. Beck JR, Pauker SG: The Markov process in medical prognosis. Med Decis Making 3:419-458, 1983
14. Treeage Software: DATA 3.0. Cambridge, MA, Treeage Software, 1997
15. Kosary CL, Ries LA, Miller BA, et al: SEER Cancer Statistics Review 1973-1992: Tables and Graphs. Bethesda, MD, National Cancer Institute, NIH publication 96-2789, 1995
16. Verhoog LC, Brekelmans CTM, Seyneaeve C, et al: Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1. Lancet 351:316-321, 1998
17. Struewing JP, Watson P, Easton DF, et al: Prophylactic oophorectomy in inherited breast/ovarian cancer families. Natl Cancer Inst Monogr 17:1529-1533, 1995
18. Hartman L, Jenkins R, Schaid D, et al: Prophylactic mastectomy (PM): Preliminary retrospective cohort analysis. Proc Am Assoc Cancer Res 38:1123, 1997 (abstr)
19. Health Care Financing Administration: Bureau of data management and strategy from the 100% medpar inpatient hospital fiscal year 1994 all inpatient by diagnosis related groups, 6/95 update. http: www.hcfa.gov/a1194drg.txt
20. Cardinale V (ed): 1996 Drug Topics Red Book - Pharmacy Fundamental Reference. Montvale, NJ, Medical Economics Company, Inc, 1996
21. Gold MR, Siegel JE, Russel LB, et al (eds): Cost-Effectiveness in Health and Medicine. New York, NY, Oxford University Press, 1996
22. Statement of the American Society of Clinical Oncology: Genetic testing for cancer susceptibility. J Clin Oncol 14:1730-1736, 1996
23. Burke W, Daly M, Garber J, et al: Recommendations for follow-up care of individuals with an inherited predisposition to cancer: II. BRCA1 and BRCA2. JAMA 277:997-1003, 1997
24. Grann VR, Panageas K, Whang W: A decision analysis of prophylactic surgery in patients positive for the BRCA1 gene test. Proc ASCO 16:1981, 1997 (abstr)
25. Brown ML, Kessler LG: The use of gene tests to detect hereditary predisposition to cancer: Economic considerations. J Natl Cancer Inst 87:1131-1136, 1995
26. Richards CS, Ward PA, Roa BB, et al: Screening for 185delAC in the Ashkenazim. Am J Hum Genet 1085-1098, 1997
27. Struewing JP, Abeliovich D, Peretz T, et al: The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nat Genet 11:198-200, 1995
28. Lerman C, Hughes C, Lemon SJ, et al: What you don't know can hurt you: Adverse psychologic effects in members of BRCA1-linked and BRGA2-linked families who decline genetic testing. J Clin Oncol 16:1650-1654, 1998
29. Lerman C, Narod S, Schulman K, et al: BRCA1 testing in families with hereditary breast-ovarian cancer: A prospective study of patient decision making and outcomes. JAMA 275:1885-1892, 1996
30. Lerman C, Seay J, Balshem A, et al: Interest in genetic testing among first-degree relatives of breast cancer patients. Am J Med Genet 57:385-392, 1995
31. Jacobsen PB, Valdimarsdottir HB, Brown KL, et al: Decision-making about genetic testing among women at familial risk for breast cancer. Psychosom Med 59:459-466, 1997
32. National Surgical Adjuvant Breast and Bowel Project (NSABP) Protocol P-1: A Clinical Trial to Determine the Worth of Tamoxifen for Preventing Breast Cancer. Pittsburgh, PA, National Surgical Adjuvant Breast and Bowel Project, 1992
33. Cummings S, Norton L, Eckert S, et al: Raloxifene reduces the risk of breast cancer and may decrease the risk of endometrial cancer in postmenopausal women: Two-year findings from the Multiple Outcomes of Raloxifene Evaluation Trial. Proc ASCO 17:3, 1998 (abstr)